<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598322</url>
  </required_header>
  <id_info>
    <org_study_id>201711014RINA</org_study_id>
    <nct_id>NCT03598322</nct_id>
  </id_info>
  <brief_title>The Volume Effect of Hydrodissection for Carpal Tunnel Syndrome</brief_title>
  <official_title>The Volume Effect of Hydrodissection for Injection Therapies in Patients With Carpal Tunnel Syndrome - Evaluation Model by Shear Wave Ultrasound Elastography and Artificial Intelligence Imaging Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators investigated the volume effect of hydrodissection for Injection therapies
      in patients with Carpal Tunnel Syndrome. The investigators evaluated participants by Shear
      Wave Ultrasound Elastography and Artificial Intelligence Imaging Analysis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators investigated the volume effect of hydrodissection for Injection therapies
      in patients with Carpal Tunnel Syndrome. The investigators evaluated participants by Shear
      Wave Ultrasound Elastography and Artificial Intelligence Imaging Analysis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2018</start_date>
  <completion_date type="Actual">July 30, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Visual analog scale (VAS)</measure>
    <time_frame>1 week, 4 weeks, 12 weeks, 24 weeks</time_frame>
    <description>Change of Visual analog scale (VAS), from Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Boston Carpal Tunnel Syndrome Questionnaire Score (BCTQ)</measure>
    <time_frame>1 week, 4 weeks, 12 weeks, 24 weeks</time_frame>
    <description>Boston Carpal Tunnel Syndrome Questionnaire Score (BCTQ), 19 items with each item scale 1-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QuickDASH</measure>
    <time_frame>1 week, 4 weeks, 12 weeks, 24 weeks</time_frame>
    <description>QuickDASH (The Disabilities of the Arm, Shoulder and Hand Score(QuickDash)), 11 items with each item scale 1-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSK US finding</measure>
    <time_frame>1 week, 4 weeks, 12 weeks, 24 weeks</time_frame>
    <description>Cross-sectional area of median nerve</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <arm_group>
    <arm_group_label>Dextrose 1mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dextrose injection, Dextrose 1mL, active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextrose 2mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextrose injection, Dextrose 2mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextrose 4mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>'Dextrose injection, Dextrose 4mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dextrose 1mL injection</intervention_name>
    <description>Dextrose 1mL injection and hydrodissection for CTS</description>
    <arm_group_label>Dextrose 1mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dextrose 2mL injection</intervention_name>
    <description>Dextrose 2mL injection</description>
    <arm_group_label>Dextrose 2mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dextrose 4mL injection</intervention_name>
    <description>Dextrose 4mL injection</description>
    <arm_group_label>Dextrose 4mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-80

          -  Electrophysiological diagnosis of carpal tunnel syndrome

          -  At least one of the following two:

               1. Tenderness or numbness over median nerve innervated dermatome over 2 months

               2. Phalen test or Tinel sign or flick sign positive

        Exclusion Criteria:

          -  History of wrist surgery

          -  Wrist trauma in recent two years

          -  Received wrist injection in recent three months

          -  History of brachial plexopathy, cervical radiculopathy or thoracic outlet syndrome

          -  History of DM, thyroid disorder or autoimmune disease

          -  Unable to cooperate with interview, examination or injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chueh Hung Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Physical Medicine &amp; Rehabilitation , National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

